Related references
Note: Only part of the references are listed.Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases
Clement Gauvain et al.
LUNG CANCER (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Noelle L. Williams et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab
Tijana Skrepnik et al.
ONCOIMMUNOLOGY (2017)
Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto et al.
JAMA ONCOLOGY (2017)
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Sagun Parakh et al.
BRITISH JOURNAL OF CANCER (2017)
Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
Elizabeth H. Byrne et al.
CANCER (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Timing and Type of Immune Checkpoint Therapy Affect the Early Radiographic Response of Melanoma Brain Metastases to Stereotactic Radiosurgery
Jack M. Qian et al.
CANCER (2016)
The immune mechanisms of abscopal effect in radiation therapy
G. Daniel Grass et al.
CURRENT PROBLEMS IN CANCER (2016)
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
E. Liniker et al.
ONCOIMMUNOLOGY (2016)
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
Ana P. Kiess et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2013)
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
Y. S. Yap et al.
BRITISH JOURNAL OF CANCER (2012)
EFFECT OF TUMOR SUBTYPE ON SURVIVAL AND THE GRADED PROGNOSTIC ASSESSMENT FOR PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Neurological complications of systemic cancer
Mustafa Khasraw et al.
LANCET NEUROLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
Eric L. Chang et al.
LANCET ONCOLOGY (2009)
Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2008)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study
SS Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma
LJ Schouten et al.
CANCER (2002)
Share Paper
